| 57.99 1.9 (3.39%) | 08-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 70.88 | 1-year : | 82.79 |
| Resists | First : | 60.68 | Second : | 70.88 |
| Pivot price | 51.81  |
|||
| Supports | First : | 49.09 |
Second : | 41.93 |
| MAs | MA(5) : | 57.7  |
MA(20) : | 50.58 |
| MA(100) : | 32.82 |
MA(250) : | 23.04 |
|
| MACD | MACD : | 4.4 |
Signal : | 3.9 |
| %K %D | K(14,3) : | 80 |
D(3) : | 81.2 |
| RSI | RSI(14): 69.6 |
|||
| 52-week | High : | 60.68 | Low : | 11.15 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TXG ] has closed below upper band by 19.6%. Bollinger Bands are 135.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 58.22 - 58.51 | 58.51 - 58.79 |
| Low: | 55.04 - 55.39 | 55.39 - 55.73 |
| Close: | 55.44 - 56 | 56 - 56.54 |
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Sun, 16 Aug 2026
10x Genomics (TXG) Could Be 35% Above Fair Value Following 2026 Outlook Lift - Yahoo Finance
Fri, 14 Aug 2026
A Look at 10x Genomics Inc (TXG) After 3.6% Decline -- GF Value $18.38 vs Price $56.09 - GuruFocus
Fri, 14 Aug 2026
10x Genomics (TXG) Q2 2026 Earnings Call Transcript - The Globe and Mail
Fri, 14 Aug 2026
10x Genomics, Inc.: Financial Data Forecasts Estimates and Expectations | TXG | US88025U1097 - marketscreener.com
Thu, 13 Aug 2026
Insider Selling: 10x Genomics (NASDAQ:TXG) Director Sells 20,000 Shares of Stock - marketbeat.com
Thu, 13 Aug 2026
10x Genomics (TXG) director John Stuelpnagel sells 20,000 shares in August 11 trades - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 117 (M) |
| Shares Float | 118 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 111.7 (%) |
| Shares Short | 16,250 (K) |
| Shares Short P.Month | 22,100 (K) |
| EPS | -0.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.3 |
| Profit Margin | -12.2 % |
| Operating Margin | -15.2 % |
| Return on Assets (ttm) | -5.1 % |
| Return on Equity (ttm) | -9.4 % |
| Qtrly Rev. Growth | -12.7 % |
| Gross Profit (p.s.) | 3.7 |
| Sales Per Share | 5.27 |
| EBITDA (p.s.) | -0.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -98.45 |
| PEG Ratio | 0 |
| Price to Book value | 9.2 |
| Price to Sales | 11 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|